Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 130 (Search time: 0.024 seconds).
Issue DateTitleAuthor(s)
2016Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHERBST, Roy S.; BAAS, Paul; PEREZ-GRACIA, Jose L.; FELIP, Enriqueta; KIM, Dong-Wan; HAN, Ji-Youn; MOLINA, Julian; KIM, Joo-Hang; ARVIS, Catherine Dubos; AHN, Myung-Ju; MAJEM, Margarita; FIDLER, Mary Jo; SURMONT, Veerle; CASTRO JR., Gilberto De; GARRIDO, Marcelo; SHENTU, Yue; DOLLED-FILHART, Marisa; IM, Ellie; GARON, Edward B.
2016Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHERBST, Roy S.; BAAS, Paul; PEREZ-GRACIA, Jose L.; FELIP, Enriqueta; KIM, Dong-Wan; HAN, Ji-Youn; MOLINA, Julian; KIM, Joo-Hang; ARVIS, Catherine Dubos; AHN, Myung-Ju; MAJEM, Margarita; FIDLER, Mary Jo; SURMONT, Veerle; CASTRO JR., Gilberto De; GARRIDO, Marcelo; SHENTU, Yue; DOLLED-FILHART, Marisa; IM, Ellie; GARON, Edward B.
2016Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1-expressing NSCLC: Updated outcomes of KEYNOTE-010HERBST, R. S.; BAAS, P.; KIM, D-W.; FELIP, E.; PEREZ-GRACIA, J. L.; HAN, J-Y.; MOLINA, J.; KIM, J-H.; ARVIS, C. Dubos; AHN, M-J. A.; MAJEM, M.; FIDLER, M. J.; CASTRO JR., G. De; GARRIDO, M.; SHENTU, Y.; LUBINIECKI, G. M.; GARON, E. B.
2016Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLCBARLESI, F.; GARON, E.; KIM, D-W.; FELIP, E.; HAN, J-Y.; KIM, J-H.; AHN, M-J. A.; FIDLER, M. J.; GUBENS, M. A.; CASTRO, G.; SURMONT, V.; LI, Q.; DEITZ, A. C.; LUBINIECKI, G.; HERBST, R. S.
2016Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNEMOK, T.; SCHMID, P.; CASTRO JR., G. de; SYRIGOS, K.; MARTIN, C.; YAMAMOTO, N.; AREN, O.; ARRIETA, O.; GOTTFRIED, M.; JAZIEH, A. R.; RAMLAU, R.; TIMCHEVA, C.; TRANI, L.
2016Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)RIECHELMANN, R.; SRIMUNINNIMIT, V.; KAVAN, P.; BARTOLOMEO, M. Di; MAIELLO, E.; CICIN, I.; KROENING, H.; GARCIA-ALFONSO, P.; CHAU, I.; FERNANDEZ-MARTOS, C.; TER-OVANESOV, M.; PEETERS, M.; PICARD, P.; BORDONARO, R.
2016Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)LINCK, R. D. M.; ASPRINO, P. F.; FREITAS, F. P.; KOYAMA, F. C.; GALANTE, P. A. F.; RIECHELMANN, R.; REIS, L. F. L.; COSTA, F. P.; HOFF, P. M.; CAMARGO, A. A.; SABBAGA, J.
2016Profile of cancer patients who visit a specialized emergency room in Sao Paulo, BrazilRAPOZO, M. M.; HATANAKA, V. M.; BERNARDES, M. C.; ALBUQUERQUE, G. M.; DIZ, M. D. P. E.
2016EVALUATION OF AN INTEGRATED CARE PATHWAY FOR RECTAL CANCER TREATMENT IMPLEMENTATION USING A LOGIC MODELKOBAYASHI, S. T.; CAMPOLINA, A. G.; SOAREZ, P. C.; JR, U. Ribeiro; DIZ, M. D.; HOFF, P. M.
2016Human papillomavirus 16 is an independent predictor of better survival among patients with early cervical cancerGENTA, M. L. N. D.; LEVI, J. E.; MARTINS, T. R.; SADALLA, J. C.; LOPEZ, R. V. M.; CARVALHO, J. P. M.; CARVALHO, J. P.